Bishop Is Named New Chair of NCAB

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 4
Volume 7
Issue 4

WASHINGTON--President Clinton has appointed J. Michael Bishop, MD, as chair of the 18-member National Cancer Advisory Board (NCAB), which advises the National Cancer Institute director. He replaces Barbara K. Rimer, DrPH, of Duke University, who resigned last fall to head the NCI’s new Division of Cancer Control and Population Science.

WASHINGTON--President Clinton has appointed J. Michael Bishop, MD, as chair of the 18-member National Cancer Advisory Board (NCAB), which advises the National Cancer Institute director. He replaces Barbara K. Rimer, DrPH, of Duke University, who resigned last fall to head the NCI’s new Division of Cancer Control and Population Science.

Dr. Bishop, an NCAB member since 1994, is professor of microbiology and immunology at the University of California, San Francisco, and was recently named as the new UCSF chancellor. He shared the 1989 Nobel Prize in Physiology and Medicine for his work on tumor viruses and oncogenes.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.